Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BA.2 DNA vaccine
- Development stage
- Preclinical
- Lead developer
- Telis Bioscience
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
**BA.2 DNA vaccine** is a preclinical plasmid DNA vaccine candidate developed by **Alvea** under its **Alveavax** platform for prevention of **COVID-19**. It is designed against antigens from the **SARS-CoV-2 Omicron BA.2 subvariant** and works by delivering DNA encoding viral antigen sequences into host cells, which then produce antigen-coding mRNA and express the antigen protein to elicit an immune response. The program was described as the first announced BA.2-specific vaccine to enter animal testing and was positioned as a scalable, shelf-stable vaccine approach intended to support distribution in low- and middle-income countries.
- Other names
- BA.2 DNA vaccineAlvea BA.2 DNA vaccineBA.2-specific DNA vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on BA.2 DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BA.2 DNA vaccine.